Regeneron Pharmaceuticals (NASDAQ:REGN) mentioned on Monday its bispecific antibody Ordspono (odronextamab) has been cleared by the European Commission for the therapy of relapsed/refractory follicular lymphoma and diffuse massive b-cell lymphoma, after two or extra traces of systemic therapy.
Ordspono is Regeneron’s (REGN) first authorised bispecific antibody and can present an off-the-shelf possibility that may be administered within the out-patient setting.
The approval was based mostly on knowledge from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, demonstrating strong and sturdy responses in each relapsed/refractory follicular lymphoma and diffuse massive B-cell lymphoma, together with within the post-CAR-T setting.
“In clinical trials, Ordspono demonstrated remarkable complete response rates in follicular lymphoma, as well as compelling efficacy results in diffuse large B-cell lymphoma, including in the post-CAR-T setting,” mentioned Stefano Luminari, Professor of Oncology on the University of Modena and Reggio Emilia, hematologist on the Hematology Unit of Arcispedale Santa Maria Nuova in Reggio Emilia, and a trial investigator.
Source: Seekingalpha